Search Results

Celligenics is pleased to announce that we have signed a memorandum of understanding with West China Hospital (Hua Xi) of Sichuan University at the 22nd Singapore-Sichuan Trade and Investment Committee Meeting. We are also pleased to announce that we have selected Chengdu as our headquarters in China, and will be developing an Advanced Therapeutics Development Centre in Chengdu’s High-Tech Industrial Development Zone. We would like to thank Enterprise (ESG) for their support in our endeavour to build a resilient and competitive global company. Read More Here: https://www.enterprisesg.gov.sg/media-centre/media-releases/2021/september/mr06621_singapore-and-sichuan-deepen-collaboration-in-trade-and-connectivity-and-innovation

Celligenics is pleased to unveil its first corporate video, titled Enabling Cellular Therapeutics. The video introduces our research team and showcases our research facility, reiterating our endeavour to achieve our vision and mission in providing accessible and affordable healthcare solutions for everyone.

Celligenics visited Changi General Hospital (CGH)'s Wound Care Clinic with the Skin Research Institute of Singapore (SRIS) yesterday, and would like to thank the doctors, nurses, and staff for hosting us at their world-class wound care treatment facilities, and sharing their invaluable insights in caring for patients with chronic wounds.

Celligenics is pleased to announce the close of our Series A fundraising exercise, raising $5.6 Mio, with Best World International (BWI) taking up at least a 12.5 per cent stake in our company. Read More Here: https://www.straitstimes.com/business/companies-markets/best-world-investing-in-astar-biomedical-spin-off-celligenics

Celligenics is pleased to announce that we have signed a Memorandum of Understanding (MOU) with our Series A investor, Best World International (BWI), and we look forward to the next stage of our strategic partnership, as we move closer towards the development and launch of our next generation of stem cell-based healthcare and wellness products.

Celligenics is pleased to announce the appointment of Dr. Pauline Tay as Chief Operating Officer. Dr. Tay joins us from the National Research Foundation (NRF), where she serves as Senior Deputy Director of Innovation and Enterprise Strategy. Dr. Tay has been credited for spearheading milestone signatures in the Singapore technology ecosystem, including the Singapore Week of Innovation and Technology (SWITCH), the NRF-Temasek IP Commercialisation Vehicle, and the National BioAccelerator Initiative. Source: https://www.convergence.events/previous-events/singapore-november-2018/singapore-speakers-nov-2018/564-dr-pauline-tay

Celligenics is honoured to have participated in a dialogue session comprising industry representatives from local biotech, venture capital, and big pharma yesterday with Dr. Tan See Leng, Minister in the Prime Minister’s Office, Second Minister for Trade and Industry and Second Minister for Manpower, organised by the Agency for Science, Technology, and Research (A*STAR), at the Experimental Drug Development Centre in Biopolis.

Celligenics is proud to have participated in the Singapore Week of Innovation and Technology (SWITCH) for our second consecutive year. Thank you everyone for visiting us at our booth, and for being part of our breakthrough.

Celligenics is proud to announce that we will be participating in the Singapore Week of Innovation and Technology (SWITCH) for our third consecutive year. We look forward to having you join us in our breakthrough later this month!

Celligenics is pleased to announce that we have signed a research collaboration agreement with local research institutes, Nanyang Technological University, Singapore's (NTU Singapore) Lee Kong Chien School of Medicine (LKCMedicine) and the Skin Research Institute of Singapore (SRIS), under the Skin Innovation Grant (SIG). This collaboration will be our staging point towards developing a therapy that accelerates healing in chronic wounds such as diabetic foot ulcers and bed sores. With our joint expertise, preliminary studies have shown outstanding results. With the support of local partners like NTU Singapore and SRIS, we are thrilled to be pioneers in bringing accessible and affordable therapies for chronic wounds to the market. Read More Here: https://www.ntu.edu.sg/news/detail/developing-therapies-that-stimulate-healing-in-chronic-wounds